Varicella vaccine given subcutaneously (under the skin). It is recommended for all children under 13 and for everyone 13 or older who has never had chickenpox. In the United States two doses are recommended. In the first case a first dose is administered at 12 to 15 months and a second dose at age 4–6 years. For people older than 13 the two doses are administered 4 to 8 weeks apart. The varicella vaccine did not become widely available in the United States until 1995. In the UK, the vaccine is only recommended in people who are particularly vulnerable to chickenpox. The
Stargardt disease long-term prognosis for patients with Stargardt disease is widely variable and depends on the age of onset and genetic alleles. The majority of people will progress to legal blindness. Stargardt disease has no impact on general health and life expectancy is normal. Some patients, usually those with the late onset form, can maintain excellent visual acuities for extended periods, and are therefore able to perform tasks such as reading or driving. A 2017 prospective epidemiologic study which recruited 81 patients with STGD over 12 months reported an incidence of between 1 and 1.28 per 10 000 individuals. The median age